Silvana Morello Selected Research

BAY 60-6583

9/2016	Activation of the A2B adenosine receptor in B16 melanomas induces CXCL12 expression in FAP-positive tumor stromal cells, enhancing tumor progression.
9/2015	Myeloid-derived suppressor cells contribute to A2B adenosine receptor-induced VEGF production and angiogenesis in a mouse melanoma model.
12/2013	Blockade of A2b adenosine receptor reduces tumor growth and immune suppression mediated by myeloid-derived suppressor cells in a mouse model of melanoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Silvana Morello Research Topics

Disease

29	Neoplasms (Cancer) 01/2022 - 11/2009
15	Melanoma (Melanoma, Malignant) 01/2022 - 05/2008
7	Inflammation (Inflammations) 01/2021 - 11/2006
4	Carcinoma (Carcinomatosis) 11/2013 - 10/2010
4	Lung Neoplasms (Lung Cancer) 06/2012 - 10/2010
3	Infections 01/2020 - 06/2010
3	Asthma (Bronchial Asthma) 11/2012 - 12/2005
2	Wounds and Injuries (Trauma) 01/2022 - 12/2007
2	Pancreatic Neoplasms (Pancreatic Cancer) 11/2021 - 10/2021
2	Helicobacter Infections 01/2020 - 01/2017
2	Edema (Dropsy) 01/2018 - 10/2015
2	Necrosis 11/2014 - 11/2009
2	Atherosclerosis 01/2014 - 04/2010
2	Neoplasm Metastasis (Metastasis) 06/2012 - 09/2011
2	Breast Neoplasms (Breast Cancer) 01/2011 - 12/2009
2	Thyroid Neoplasms (Thyroid Cancer) 11/2009 - 02/2008
2	Chronic Obstructive Pulmonary Disease (COPD) 02/2006 - 12/2005
1	Disease Progression 01/2022
1	Carcinogenesis 01/2022
1	Brain Neoplasms (Brain Tumor) 12/2020
1	Hypersensitivity (Allergy) 01/2020
1	Bronchial Hyperreactivity 01/2020
1	Lung Injury 01/2020
1	Pleural Effusion (Pleural Effusions) 01/2019
1	Pleurisy (Pleuritis) 01/2019
1	Stomach Ulcer (Gastric Ulcer) 01/2018
1	Hypoxia (Hypoxemia) 01/2018
1	Experimental Melanoma 09/2016
1	Rheumatoid Arthritis 01/2016

Drug/Important Bio-Agent (IBA)

17	Adenosine (Adenocard)FDA LinkGeneric 01/2022 - 11/2006
10	Purinergic P1 Receptors (Adenosine Receptor)IBA 01/2019 - 02/2006
9	CytokinesIBA 01/2022 - 10/2010
5	EnzymesIBA 01/2021 - 01/2013
4	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2022 - 06/2011
4	NivolumabIBA 01/2022 - 12/2017
4	Adenosine Triphosphate (ATP)IBA 01/2022 - 03/2016
4	CarrageenanIBA 01/2019 - 12/2007
4	N(6)- (3- iodobenzyl)- 5'- N- methylcarboxamidoadenosineIBA 01/2012 - 02/2008
3	Interleukin-17 (Interleukin 17)IBA 01/2022 - 09/2012
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2022 - 11/2009
3	Biomarkers (Surrogate Marker)IBA 11/2020 - 12/2017
3	adenylyl(3'-5')cytidine-3'-phosphateIBA 01/2019 - 09/2012
3	Proteins (Proteins, Gene)FDA Link 09/2016 - 02/2006
3	BAY 60-6583IBA 09/2016 - 12/2013
3	1-propyl-8-(4-sulfophenyl)xanthineIBA 09/2016 - 12/2013
3	Adenosine A2B ReceptorIBA 09/2015 - 11/2012
3	Toll-Like Receptors (Toll-Like Receptor)IBA 09/2011 - 04/2010
2	pembrolizumabIBA 01/2022 - 12/2020
2	Interleukin-12 (IL 12)IBA 01/2022 - 11/2014
2	Interleukin-6 (Interleukin 6)IBA 01/2022 - 01/2017
2	Annexin A1IBA 11/2021 - 10/2021
2	NucleosidesIBA 01/2021 - 03/2016
2	CTLA-4 AntigenIBA 12/2020 - 01/2014
2	5'-Nucleotidase (5' Nucleotidase)IBA 01/2020 - 01/2019
2	Trefoil Factor-1IBA 01/2020 - 01/2017
2	AllergensIBA 01/2020 - 11/2012
2	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 01/2019 - 12/2013
2	Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)IBA 01/2018 - 09/2016
2	Adenosine A2A Receptor (Adenosine A2A Receptors)IBA 01/2018 - 01/2014
2	Pharmaceutical PreparationsIBA 01/2016 - 11/2009
2	Interleukin-10 (Interleukin 10)IBA 12/2013 - 05/2011
2	LigandsIBA 09/2011 - 06/2011
2	OligodeoxyribonucleotidesIBA 05/2011 - 10/2010
2	Propolis (Bee Bread)IBA 01/2011 - 12/2009
1	Saline SolutionIBA 01/2022
1	Fibronectins (Fibronectin)IBA 01/2022
1	mesoglycanIBA 01/2022
1	Interleukin-1beta (Interleukin 1 beta)IBA 01/2022
1	Interferon-gamma (Interferon, gamma)IBA 01/2022
1	5- amino- 7- (2- phenylethyl)- 2- (2- furyl)pyrazolo(4,3- e)- 1,2,4- triazolo(1,5- c)pyrimidineIBA 01/2022
1	cadherin 5IBA 01/2022
1	VimentinIBA 01/2022
1	Transforming Growth Factor beta (TGF-beta)IBA 01/2022
1	Urea (Carbamide)FDA LinkGeneric 11/2021
1	CD39 antigenIBA 01/2021
1	Adenosine Monophosphate (AMP)IBA 12/2020
1	AntibodiesIBA 12/2020
1	Programmed Cell Death 1 ReceptorIBA 12/2020
1	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 12/2020
1	tetrathiomolybdate (ammonium tetrathiomolybdate)IBA 01/2020
1	Chelating AgentsIBA 01/2020
1	CopperIBA 01/2020
1	Immunoglobulin E (IgE)IBA 01/2020
1	Immunologic Factors (Immunomodulators)IBA 01/2020
1	OvalbuminIBA 01/2020
1	Biological ProductsIBA 01/2019
1	MitogensIBA 01/2018
1	2- (4- (2- carboxyethyl)phenethylamino)- 5'- N- ethylcarboxamidoadenosineIBA 01/2018
1	Protective AgentsIBA 01/2017
1	Peptides (Polypeptides)IBA 01/2017
1	MucinsIBA 01/2017
1	Messenger RNA (mRNA)IBA 01/2017
1	plerixafor FDA Link 09/2016
1	AlginatesIBA 01/2016
1	Prednisolone (Predate)FDA LinkGeneric 01/2016
1	gellan gumIBA 01/2016
1	Hypromellose DerivativesIBA 01/2016

Therapy/Procedure

9	Therapeutics 01/2022 - 06/2010
2	Immunotherapy 01/2022 - 01/2019
2	Drug Therapy (Chemotherapy) 01/2018 - 10/2010